Saturday 17 October 2026
Export MAZE’s income statement to Excel — free account
Maze Therapeutics, Inc.
MAZE Healthcare Biotechnology
Maze Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $167.5 million. In the quarter to June 2026, EPS grew 1.30% and free cash flow grew 50.2%, each against the same quarter a year earlier.
27.53
0.05
+0.18%
Follow MAZE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
— | 0.00 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (41.13) | — | — | |
P/B ratio |
— | 4.71 | — | — | |
Price to Tangible BV |
— | 4.71 | — | — | |
EV/Sales |
— | 0.00 | — | — | |
EV/EBITDA |
— | 0.00 | — | — | |
EV/Operating CF |
— | (10.66) | — | — | |
EV/FCF |
— | (10.61) | — | — | |
Quick Ratio |
17.90 | 17.54 | 15.16 | 17.36 | |
Current Ratio |
18.31 | 17.88 | 15.50 | 17.70 | |
Net Debt/EBITDA |
7.83 | 12.18 | 9.10 | 11.85 | |
Debt/Assets |
7.33% | 9.25% | 0.00% | 0.00% | |
Debt/Equity |
0.09 | 0.11 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.34 | 1.62 | 0.80 | 0.82 | |
Capex/Depreciation |
(0.21) | (0.11) | (0.07) | (0.12) | |
Interest Coverage |
(51.60) | (30.66) | — | — | |
Research and Development Expense of Revenue |
0.00% | 170.74% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 62.03% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 35.55% | 0.00% | 0.00% | |
Graham Net Nets |
— | 0.19 | — | — | |
Graham Number |
— | 0.00 | — | — | |
Earnings Yield |
— | (8.48%) | — | — | |
Free Cash Flow Yield |
— | (7.59%) | — | — | |
Revenue per Share |
0.00 | 0.37 | 0.00 | 0.00 | |
Operating CF per Share |
(0.26) | (0.73) | (0.65) | (0.54) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.26) | (0.73) | (0.65) | (0.54) | |
Cash per Share |
6.97 | 6.54 | 7.96 | 8.39 | |
Shareholders Equity per Share |
7.68 | 6.34 | 8.26 | 8.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.68 | 6.34 | 8.26 | 8.29 | |
Free Cash Flow |
(15.16) | (39.21) | (27.76) | (24.71) | |
Working Capital |
397.46 | 358.54 | 327.16 | 369.19 | |
Capital Expenditures |
(0.11) | (0.09) | (0.03) | (0.07) | |
Net Current Asset Value |
341.92 | 301.77 | 307.56 | 348.68 | |
EV/EBIT |
— | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
2.94 | 3.21 | 1.87 | 2.47 | |
Average Assets |
417.57 | 376.28 | 318.83 | 246.78 | |
Average Common Equity |
357.68 | 316.88 | 21.89 | 2.79 |
Columns are period end dates